Archive | Redefining Early Stage Investments (RESI) RSS feed for this section

Digital RESI JPM Winners

20 Jan

By Megan Rychwa, Investor Research Analyst, LSN

Last week, Life Science Nation wrapped up its second Digital RESI JPM and the first Innovators Pitch Challenge (IPC) of the year. As we prepare for Digital RESI March, we wanted to take this opportunity to announce and celebrate the winners of Digital RESI JPM IPC!

Learn more about the winners below and how their technology is making a difference in the early-stage life science ecosystem. The winners are picked by the votes cast from RESI attendees with exclusive access to the live IPC session and dedicated company landing pages and pitch materials.

The IPC returns March 22-24. Eligible startups can apply until Friday, February 25. All qualifying finalists must purchase a Digital RESI March registration and pay a $800 pitch fee. We accept applications on a rolling basis, so get yours in today!


First Place – Amplified Sciences
Amplified Sciences is a startup life science diagnostics company focused on accurately detecting and pre-empting the risks of debilitating diseases, including lethal cancers and organ loss with R&D operations in Purdue Research Park and research alliances in San Francisco and Boston. The company is developing a portfolio of diagnostic assays for early detection of disease. An ultra-sensitive molecular sensing technology licensed from Purdue operates with novel test-strips that combine with portable instrumentation to form a highly versatile clinical assay platform that can scale to point of care. The lead assay in development is at clinical testing stage and targets early detection of undiagnosed pancreatic cancers. The company closed a Seed round in 2020 which will enable technical and clinical validation of the PanCystPro product and position the company for entry into a commercializable lab-developed test in 2023.

Second Place – OncoXome
OncoXome is an oncology startup whose objective is to bring to patients with advanced cancer an innovative multitarget therapeutic approach hacking cell communication and using gene editing to overcome cancer resistance. They have two platforms: proprietary exosome scalable production and gene editing therapy. Combined, these platforms lead to targeted therapeutic delivery. They first target patients with advanced KRAS mutated lung, colorectal and pancreatic cancers.

Third Place – Prolifagen
Prolifagen is a Start Up company located in Philadelphia and working on a local injectable medicine based on microRNA to regenerate heart muscle damaged by MI and prevent heart failure.  [Approximately 400,000 people develop HF following massive MI yearly in US/EU combined, at a huge cost to society.] They have shown regeneration of cardiac muscle in mice and have early data of regeneration in pigs.  The next milestone will be to define the extent of clinical benefit in a pig model of myocardial infarct, as a steppingstone to clinical trials. They have issued patents in US/EU. So far, their funding has been based on non-dilutive funding from founders and on a phase 1 SBIR grant. They are looking for strategic investment and/or collaboration/licensing.


Digital RESI March Agenda

20 Jan

By Rory McCann, Marketing Manager & Conference Producer, LSN

It’s no secret that January is a time for action – new resolutions, new fundraising campaigns, and, of course, the annual J.P. Morgan Healthcare week – the Olympic torch of life science deal flow. At Life Science Nation, we know that fundraising is a numbers game, and just because January is winding down, doesn’t mean the early-stage ecosystem is. This is why the Redefining Early Stage Investments (RESI) conference series picks up where we left off March 22-24 with a whole new lineup of panels, workshops, pitch sessions, partnering, and more!

Check out our preliminary agenda and visit our website to learn more and see how you can get involved in Digital RESI March! Innovator’s Pitch Challenge applications are open until Friday, February 25, and panel recruitment is ongoing, so if you’re a fit for a panel topic, or if your company is ready to get in front of the right investors for your product and stage of development, contact us to learn more!

Digital RESI March 22-24, 2022 Agenda
Tuesday Wednesday Thursday
10AM EST IPC Session #1 Mental & Behavioral Health Panel IPC Session #8
IPC Session #5
11aM EST Early Stage Therapeutics Panel Age-Tech Devices Panel Precision Medicine Panel
12PM EST First Republic Bank
Burns & Levinson
1PM EST IPC Session #2 IPC Session #6 Cell & Gene Therapy Panel
IPC Session #9
2PM EST Longevity, Health & Wellness Panel Medtech Strategics Panel Defining AI Investment Panel
3PM EST Seed Funds Panel AI Drug Discovery & Development Panel IPC Session #10
IPC Session #3
4PM EST Tales from the Road: AI Innovators on their Fundraising Journey Tales from the Road: Biotech and MedTech Innovators on their Fundraising Journey Tales from the Road: Age-Tech Innovators on their Fundraising Journey
5PM EST IPC Session #4 IPC Session #7 IPC Session #11


RESI’s 2022 Outlook

20 Jan

By Karen Deyo, Director of Investor Research, Israel BD, LSN

2022 is off to a fantastic start with Digital RESI JPM bringing together companies, investors and service providers from 30 countries over 5 continents in a 3-day event full of partnering meetings, investor panels, pitch sessions and workshops.

Life Science Nation has found a formula that works for digital events, and while we look forward to when we can safely return to in-person events, we will continue to offer virtual events to help move the needle in the life sciences. We hope to return to in-person events in June, but will offer options to make our events safe for all.

Make sure to mark your calendars for the following RESI conferences, planned for 2022!

  • Digital RESI, March 22-24 – (virtual)
  • RESI, June 14-16 – San Diego (in-person and virtual)
  • RESI, September 20-22 – Boston (in-person and virtual)
  • RESI, November 15-17 – To be Announced (in-person and virtual)

Registration for Digital RESI March is now open, so make sure to register before the Super Early Bird pricing ends on January 28!


Companies to Watch in 2022

13 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Partnering Conference Series

For the past ten years, Life Science Nation (LSN) has built a global partnering platform that matches scientist-entrepreneurs and fundraising CEOs with capital, licensing and product collaboration partners. In that time, LSN has learned so much about what makes a compelling fit for our buyside partners. I have had discussions with hundreds of investors, and I always want to understand how their investment theme of seeking early-stage technology assets is balanced with the risk of going early. Unsurprisingly, it’s complicated, but it typically revolves around focusing on key attributes of the company, the science, the management team, key milestones already achieved, and the all-important data that supports that the technology is heading in the right direction.

Similarly, I have developed my own set of attributes that I personally look for when I meet the companies that are referred to me through LSN’s relationship with regional tech hubs, incubators, and accelerators or national government and state life science agencies. These are what I look for:

  • The Founding Scientist – Is there a scientist with a long lineage with the key science and the technology assets inside the company? A lot of the “new” technologies are actually the latest iteration of technologies that have been worked on for decades. When the scientist that is associated with that technology is still involved either as CTO, advisory or board compacity, that helps de-risk the opportunity. Having the world-renowned expert onboard and that thread of historical continuity provides not only perspective, but credence to the validation and the translating of the technology. Even if the assets are not that old, a thorough comprehension of the history, context, and potential show potential partners that the technology is in the hands of leadership with an appropriate understanding and appreciation of what it is capable of.
  • The CEO – There are a few categories of CEO that I see in many of these startups. Experience matters and which side of the house the startup CEO has been on in the past matters and will affect how the company addresses the challenges that will surface along the startup journey. Personally, I have an affinity for the CEOs who were mid-level executives in big drug or device companies, and who were responsible for managing and getting successful products out the door in the past. It is even better when one or more of those products was a blockbuster. This type of CEO that has been-there-done-that in a corporate play and now wants to take all that knowledge, expertise, and leverage it in a new startup. I then ask myself, “Can this CEO listen? Is he/she coachable with an ability to learn quickly and discern, accept, and apply sound feedback?”
  • Management Team – I like a diverse management team with similar experience as described above that augments and complements the CEO. A CEO should not surround themself with a team that closely resembles their own strength and skillset. A savvy CEO will build a team with relevant experience and together possess expertise in how the game is played. They understand from past corporate experience when to hold them, when to fold them, and when to pivot. A diverse professional team that has seen success in the past and now wants to take their startup to the big leagues will generate traction and get their exit.
  • Milestones and Data – Show a cogent well-thought-out plan based on hitting realistic achievable milestones that will produce compelling, validating data to show that the product is on the right path and going in the right direction. CEOs and their teams gain credibility when they present this aspect honestly and correctly, and when they are not coordinated, they lose credibility, and thus a chance for partnerships. Having realistic milestones that will produce compelling validating data is crucial to partnering.
  • Entrepreneurial Agency – I have been talking about entrepreneurial agency for a while now. It’s hard to describe, but you know it when you see it. It’s the vibe you get, the confidence that is exuded, the passion, the professionalism, the unbridled desire, and determination. Entrepreneurial agency gives a company mojo which, in turn, creates positive propulsion forward. I mentioned that I like to see seasoned CEOs with experience in large enterprises that are now leading startups and taking their shot. However, there remain many seats at the table for the young, dynamic CEO that has followed their passion and their love for finding a scientific solution for an unmet medical need and wants to impact the healthcare arena. There are plenty of both types of CEOs in the early-stage arena, and that is driving this golden age of life science that we are all living in.

Keeping in mind the outline above, I would like to name my list of “Companies to Watch in 2022.”  I have been exposed to all these companies and have watched them as they have progressed and grown. I like where they are at and where they are headed. I have not done any scientific diligence or evaluated them for any other third-party entities. I have compiled this list to showcase these companies as potential up-and-comers in the life science arena for Next Phase newsletter readers and RESI Conference attendees. Companies to Watch in 2022… Drum roll please…

AHEAD Medicine
AHEAD focuses on developing AI-enabled diagnostics and clinical decision support for blood cancers with the vision to provide efficient, comprehensive and high-fidelity diagnostic and disease evaluation solutions to support physicians in optimizing treatment plan for patients with hematologic malignancies. Listen to a past interview with AHEAD Medicine CEO, Andrea Wang.

Embrace Prevention Care
Embrace Prevention Care’s Medicare-covered nurse practitioners use Personal Prevention Care to help older adults focus on the most important steps to manage heart failure and other chronic conditions, so they stay healthy, independent, and living in their homes. Listen to a past interview with Embrace Prevention Care CEO, David Dlesk.

Ethismos Research
Ethismos Research, Inc. is a clinical stage pharmaceutical/drug development company based in Cambridge, Massachusetts. Ethismos’ new approach to pain targets the acute to chronic pain transition; reduces exposure to opioids in patients with disabling chronic pain; and addresses weaknesses of chronic ketamine for treatment resistant depression.

FIGUR8 is on a mission to bring a new standard of care to musculoskeletal health through intuitive software and sensor technology that leverages Artificial Intelligence to drive a precise data-driven approach to MSK care.

MindLab is a biopharmaceutical company focused on developing and commercializing novel therapeutic products for the treatment of pain management disorders that address the prevalent issues of addiction, tolerance, side effects, durability, and adherence. Our mission is to ensure that no one suffers from pain without adequate treatment. Listen to a past interview with MindLab CEO, Larry Raoul James.

NanoPharmaceuticals LLC is an emerging pharmaceutical company devoted to the discovery and commercialization of new, molecularly targeted drugs for diseases with major unmet needs.

Quantaras Contour Companion is an FDA-cleared, cloud-based, software-only medical device that performs auto-contouring of organs at risk in the Head and Neck and Thorax. Listen to a past interview with Quantaras CEO, Joe Camaratta.

Reglagene’s mission is to discover and develop low-cost and noninvasive therapeutic solutions that selectively cause damage in cancer cells while sparing healthy cells, effectively disrupting the chemotherapeutic space. Listen to a past interview with Reglagene CEO, Richard Austin.

Reiley Pharmaceuticals
Reiley Pharmaceutical Inc. (RPI) is a precision medical company developing diagnostic imaging drugs, to illuminate the exact location of pain which enables standard hospital scanners to quickly and accurately identify and image the precise location of the pain source, solving the hardest challenge in LBP diagnostics.

Terra BioWorks
Terra Bioworks can clone large microbial DNA pathways very precisely, extracting specific sections, and reprogram several types of microbes, that serve as microbial factories, to manufacture new and existing natural product drugs, all of which will disrupt the CMO landscape. Listen to a past interview with Terra BioWorks CEO, David Mead.

Digital RESI March Registration Opens

13 Jan

By Rory McCann, Marketing Manager & Conference Producer, LSN

Digital RESI March registration is now open! The Redefining Early Stage Investments (RESI) 2022 conference series continues March 22-24 in a virtual format. RESI is a partnering conference that is dedicated to connecting early-stage founders in life science and healthcare with capital, licensing, and strategic partnerships that are a fit for their product and stage of development.

The RESI partnering platform enables attendees to filter through hundreds of investors, service providers, and technology assets to find the best fit for their needs. Additionally, RESI organizes expert panels and educational workshops to provide insights into the industry and teach skills to help entrepreneurs fundraise successfully. RESI is also unique in its Innovator’s Pitch Challenge, which provides a platform for fundraising founders to pitch directly to a panel of active investors in their sector applications are open!

RESI is a one-stop-shop for all buyers and sellers in the early-stage arena. Startups looking to partner with 350+ investors can save $300 when they register for Digital RESI March by January 28. Learn more about offerings for investors and service providers and reach out to see how RESI can help in your fundraising journey!

Digital RESI March Innovator’s Pitch Challenge

13 Jan

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN


As Digital RESI JPM comes to a close, we are now accepting applications for the Innovator’s Pitch Challenge (IPC) at our next conference, Digital RESI, March 22-24. In 2021, hundreds of companies participated in the IPC to boost their exposure to the RESI community and engage meaningfully with investors and strategic partners with aligned interests. 2022 is already off to a good start and we look forward to continue showcasing incredible technologies across therapeutics, medical devices, diagnostics, digital health, life science tools, and more.

We are accepting applications until Friday, February 25. Please apply by clicking the button below:

2021 IPC Winners

2022 Fundraising is Here – Are you?

6 Jan

By Rory McCann, Marketing Manager & Conference Producer, LSN

Only a few days into the new year and already one of the biggest fundraising events of the year is starting. Digital RESI JPM, January 11-13 partnering is open and vibrant with hundreds of attendees taking advantage of the opportunities available to fundraising entrepreneurs in 2022. There is still time to sign up for early-stage companies seeking capital, licensing, and strategic partnerships, but even more importantly is the yearlong ecosystem of partnering that companies at all stops along their early-stage journey can take advantage of.

If 2022 is your year to kick your fundraising into high gear, check out the Digital RESI JPM agenda, as well as the plethora of events and services available to help you meet your goals and be successful in the new year.

  Tuesday (1/11) Wednesday (1/12) Thursday (1/13)
10AM EST Innovator’s Pitch Challenge #1 Devices & Diagnostics Family Offices Panel Innovator’s Pitch Challenge #8 Longevity-Devices & Digital Health
Innovator’s Pitch Challenge #5 Oncology Therapeutics & AI Drug Discovery Applications
11AM EST Medical Devices Investor Panel Defining and Funding Age-Tech Innovations Panel Diagnostics Investor Panel
12PM EST Negotiating Term Sheets Licensing in Life Sciences How to Evaluate Your Banking Partner Workshop
1PM EST Innovator’s Pitch Challenge #2 Therapeutics Innovator’s Pitch Challenge #6 Diagnostics & Digital Health Innovator’s Pitch Challenge #9 Devices and R&D Services
 Fundraising Challenges and Highlights of First-Time Founders & CEOs
2PM EST The Regulatory Pathway for AI in Healthcare Panel Digital Health Investor Panel Emerging Products and Technologies for Aging at Home Panel
3PM EST Big Pharma Panel The Early Stage Pivot Panel Corporate VC Panel
Innovator’s Pitch Challenge #3 Oncology Diagnostics Innovator’s Pitch Challenge #10 Medical Devices
4PM EST Tales from the Road: Age-Tech Innovators on their Fundraising Journey Tales from the Road: Biotech and MedTech Innovators on their Fundraising Journey Tales from the Road: AI Innovators on their Fundraising Journey
5PM EST Innovator’s Pitch Challenge #4 AI-Devices & Digital Health Innovator’s Pitch Challenge #7 Therapeutics Innovator’s Pitch Challenge #11 Oncology Therapeutics
Longevity Investors Share Their Investment Thesis Longevity Entrepreneurs Discuss Their New Products
%d bloggers like this: